soul trial oral semaglutide cardiovascular outcomes results 2025 nejm 🧿 is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM Oral Semaglutide Cuts Cardiovascular Risk

Omega-3 index data were categorized into tertiles (lowest, middle, and highest tertile)

A proposed clinical staging system for obesity

Viollet B, Athea Y, Mounier R, Guigas B, Zarrinpashneh E, Horman S, et al

Each bottle contains 60 capsules.

Novo Nordisk offers the Novo Nordisk Patient Assistance Program (PAP) for people with Type 2 diabetesone of the weight-related conditions Wegovy is approved for in patients with a BMI of 27 or higher

Activated platelets release mediatorsserotonin, thromboxane A, adenine nucleotides, stromal-derived factor-1, and transforming growth factor-that mitigate cardiomyocyte death during ischemia [148,149,150]